These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15282678)

  • 1. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC; Ng DM; Fong DY; Ha SY; Lau YL
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH; De Abreu Lourenço R; Dalton A; Houltram J; Dowton D; Joshua DE; Lindeman R; Ho PJ
    Value Health; 2007; 10(6):451-6. PubMed ID: 17970927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of winged Vialon cannulae and metal butterfly needles.
    Dawkins L; Britton D; Johnson I; Higgins B; Dean T
    Int J Palliat Nurs; 2000 Mar; 6(3):110-6. PubMed ID: 11051946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 13. A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.
    Elalfy MS; Massoud W; Elsherif NH; Labib JH; Elalfy OM; Elaasar S; von Mackensen S
    Pediatr Blood Cancer; 2012 Jun; 58(6):910-5. PubMed ID: 22232075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to deferoxamine therapy: heeding Hippocrates and Osler.
    Olivieri NF
    Am J Hematol; 2004 Aug; 76(4):415-6. PubMed ID: 15282681
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.